Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 795

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Open access
Eyck, Ben M., van Lanschot, J. Jan B., Hulshof, Maarten C. C. M., van der Wilk, Berend J., Shapiro, Joel, van Hagen, Pieter, van Berge Henegouwen, Mark I., Wijnhoven, Bas P. L., van Laarhoven, Hanneke W. M., Nieuwenhuijzen, Grard A. P., Hospers, Geke A. P., Bonenkamp, Johannes J., Cuesta, Miguel A., Blaisse, Reinoud J. B., Busch, Olivier R., Creemers, Geert-Jan M., Punt, Cornelis J. A., Plukker, John Th. M., Verheul, Henk M. W., Spillenaar Bilgen, Ernst J., van der Sangen, Maurice J. C., Rozema, Tom, ten Kate, Fiebo J. W., Beukema, Jannet C., Piet, Anna H. M., van Rij, Caroline M., Reinders, Janny G., Tilanus, Hugo W., Steyerberg, Ewout W., van der Gaast, Ate, for the CROSS Study Group·2021·Journal of Clinical Oncology

Abstract

PURPOSE: Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resectable esophageal or junctional cancer. We aimed to assess long-term outcome of this regimen. METHODS: From 2004 through 2008, we randomly assigned 366 patients to either five weekly cycles of carboplatin and paclitaxel with concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week) followed by surgery, or surgery alone. Follow-up data were collected through 2018. Cox regression analyses were performed to compare overall survival, cause-specific survival, and risks of locoregional and distant relapse. The effect of neoadjuvant chemoradiotherapy beyond 5 years of follow-up was tested with time-dependent Cox regression and landmark analyses. RESULTS: The median follow-up was 147 months (interquartile range, 134-157). Patients receiving neoadjuvant chemoradiotherapy had better overall survival (hazard ratio [HR], 0.70; 95% CI, 0.55 to 0.89). The effect of neoadjuvant chemoradiotherapy on overall survival was not time-dependent ( P value for interaction, P = .73), and landmark analyses suggested a stable effect on overall survival up to 10 years of follow-up. The absolute 10-year overall survival benefit was 13% (38% v 25%). Neoadjuvant chemoradiotherapy reduced risk of death from esophageal cancer (HR, 0.60; 95% CI, 0.46 to 0.80). Death from other causes was similar between study arms (HR, 1.17; 95% CI, 0.68 to 1.99). Although a clear effect on isolated locoregional (HR, 0.40; 95% CI, 0.21 to 0.72) and synchronous locoregional plus distant relapse (HR, 0.43; 95% CI, 0.26 to 0.72) persisted, isolated distant relapse was comparable (HR, 0.76; 95% CI, 0.52 to 1.13). CONCLUSION: The overall survival benefit of patients with locally advanced resectable esophageal or junctional cancer who receive preoperative chemoradiotherapy according to CROSS persists for at least 10 years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.03614

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 795

Metadata

Authors
Eyck, B. M., van Lanschot, J. J. B., Hulshof, M. C. C. M., van der Wilk, B. J., Shapiro, J., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., Cuesta, M. A., Blaisse, R. J. B., Busch, O. R., Creemers, G.-J. M., Punt, C. J. A., Plukker, J. T. M., Verheul, H. M. W., Spillenaar Bilgen, E. J., van der Sangen, M. J. C., Rozema, T., ten Kate, F. J. W., Beukema, J. C., Piet, A. H. M., van Rij, C. M., Reinders, J. G., Tilanus, H. W., Steyerberg, E. W., van der Gaast, A., & for the CROSS Study Group
Venue
Journal of Clinical Oncology
Published
2021-06-20
Volume
39
Issue
18
Pages
1995-2004
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3154482193
Cited by
795
References
24
FWCI
99.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. https://app.cochat.ai/papers/10.1200/jco.20.03614
The paper
Eyck, B. M., van Lanschot, J. J. B., Hulshof, M. C. C. M., van der Wilk, B. J., Shapiro, J., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., Cuesta, M. A., Blaisse, R. J. B., Busch, O. R., Creemers, G.-J. M., Punt, C. J. A., Plukker, J. T. M., Verheul, H. M. W., . . . for the CROSS Study Group. (2021). Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.03614

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.